Research Article
Acute Ischaemic Stroke in Patients Treated with Direct Oral Anticoagulants: Potential Causes, Clinical Characteristics, and Short-Term Outcomes
Table 1
Characteristics of DOAC-treated subgroup.
| | Personal information | | Age (median (IQR)) | 77 (IQR 38–98) | | Female sex ( (%)) | 66 (60.6%) | | DOAC | | Dabigatran ( (%)) | 33 (30.3%) | | Rivaroxaban ( (%)) | 47 (43.1%) | | Apixaban ( (%)) | 29 (26.6%) | | Reason for DOAC treatment | | AF ( (%)) | 101 (92.7%) | | Thromboembolism ( (%)) | 4 (3.7%) | | COMPASS trial dose ( (%)) | 3 (2.7%) | | Unknown ( (%)) | 1 (0.9%) | | The last dose of DOAC before admission ( (%)) | | <12 hours | 26 (23.9%) | | 12-24 hours | 10 (9.2%) | | 24-48 hours | 5 (4.6%) | | >48 hours | 15 (13.8%) | | Unknown | 53 (48.6%) | | Compliance ( (%)) | | Full compliance | 24 (22.0%) | | Noncompliance | 29 (26.6%) | | Unknown | 56 (51.4%) | | DOAC dose | | Full ( (%)) | 49 (45%) | | Reduced ( (%)) | 53 (48.6%) | | Dabigatran | 12 (22.6%) | | Rivaroxaban | 26 (49.1%) | | Apixaban | 15 (28.3%) | | On-label underdosing | 33 (62.3%) | | Off-label underdosing | 17 (32.1%) | | 2 (11.8%) = dabigatran | | 6 (35.3%) = rivaroxaban | | 9 (52.9%) = apixaban | | COMPASS trial rivaroxaban dose | 3 (5.7%) | | Unknown ( (%)) | 7 (6.4%) | | A potential cause of DOAC treatment failure ( (%)) | 63 (57.8%) | | Valvular AF ( (%)) | 3 (2.7%) | | Hereditary thrombophilia ( (%)) | 2 (1.8%) | | Concomitant malignancy ( (%)) | 8 (7.3%) | | Carotid atherosclerosis with hemodynamically significant stenoses ( (%)) | 19 (19.4%) | | Lacunar stroke ( (%)) | 4 (3.7%) | | Significant drug-drug interactions ( (%)) | 1 (0.9%) | | APTT | | Available h from stroke onset ( (%)) | 73 (66.9%) | | APTT (median (IQR)) | 31.6 (IQR 20.9–69.9) seconds |
|
|
DOAC = direct oral anticoagulants; AF = atrial fibrillation; APTT = activated partial thromboplastin time.
|
